Penicillin Salt Prices Drop To Rock Bottom
This article was originally published in PharmAsia News
Penicillin industrial salt, China's number one active pharmaceutical ingredient, has seen prices slipping since last year's fourth quarter to hit almost historic lows. According to statistics, penicillin salt export dropped to only 415 metric tons last November, a record low in three years. Industry observers believe prices will continue to decline as overseas orders are put on hold on expectation of further price erosion. Meanwhile, trading companies dumping their stock and United Laboratories' penicillin salt production just coming online add pressure to an already battered market. Analysts forecast a gloomy outlook for the industry this year. (Click here for more)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.